Nanoligent, is a Spanish spin-off biotechnology company established in 2017 at IR-Sant Pau and UAB, dedicated to advancing the clinical development of our targeted protein nanomedicines. Nanoligent’s mission is to revolutionize precision oncology through the development of nanomedicines that selectively target the CXCR4 receptor, which is expressed in more than 20 different tumor types. By delivering therapeutic payloads with unparalleled accuracy, the company is committed to reducing systemic toxicity, enhancing treatment efficacy, and transforming cancer therapy. This innovative approach enables precision targeting and selective depletion of cancer cells while sparing healthy tissues, offering a high therapeutic index and minimal side effects. These advancements aim to redefine the future of oncology treatments, making them safer and more effective for improving patients’ lives.

Our group plays a pivotal role in the design and development of the nanomedicine candidates currently in Nanoligent’s pipeline. In this sense, all the patents supporting the company’s technology have been licensed from our group. Additionally, Dr. Ugutz Unzueta, the Principal Investigator of our team, actively collaborates with Nanoligent as Scientific Advisor and CMC operational lead, ensuring our research is integrated into their clinical development strategies.

Web: www.nanoligent.com